Last reviewed · How we verify
Perflutren lipid
Perflutren lipid is a Ultrasound contrast agent Small molecule drug developed by UNC Lineberger Comprehensive Cancer Center. It is currently FDA-approved for Echocardiography contrast enhancement for left ventricular opacification, Ultrasound imaging of blood flow and tissue perfusion. Also known as: Definity®, Definity.
Perflutren lipid microbubbles enhance ultrasound imaging by providing acoustic contrast through gas-filled lipid shells that reflect ultrasound waves.
Perflutren lipid microsphere is a small molecule used as a diagnostic agent. It has been studied in various clinical trials for conditions such as soft tissue sarcoma, stress echocardiography, kidney cancer, scleral buckling, and cardiovascular disease.
At a glance
| Generic name | Perflutren lipid |
|---|---|
| Also known as | Definity®, Definity |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Drug class | Ultrasound contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Perflutren lipid microbubbles are composed of perfluorocarbon gas encapsulated in a lipid shell. When exposed to ultrasound, these microbubbles oscillate and reflect the ultrasound waves back to the transducer, significantly enhancing image contrast and allowing better visualization of blood flow and tissue perfusion. This enables improved diagnostic imaging capabilities for echocardiography and other ultrasound applications.
Approved indications
- Echocardiography contrast enhancement for left ventricular opacification
- Ultrasound imaging of blood flow and tissue perfusion
Common side effects
- Headache
- Nausea
- Chest discomfort
- Flushing
Key clinical trials
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy (EARLY_PHASE1)
- Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer (PHASE2, PHASE3)
- Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses (PHASE1)
- Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
- Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging (PHASE2)
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer (PHASE1)
- Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension (NA)
- Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perflutren lipid CI brief — competitive landscape report
- Perflutren lipid updates RSS · CI watch RSS
- UNC Lineberger Comprehensive Cancer Center portfolio CI
Frequently asked questions about Perflutren lipid
What is Perflutren lipid?
How does Perflutren lipid work?
What is Perflutren lipid used for?
Who makes Perflutren lipid?
Is Perflutren lipid also known as anything else?
What drug class is Perflutren lipid in?
What development phase is Perflutren lipid in?
What are the side effects of Perflutren lipid?
Related
- Drug class: All Ultrasound contrast agent drugs
- Manufacturer: UNC Lineberger Comprehensive Cancer Center — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for Echocardiography contrast enhancement for left ventricular opacification
- Indication: Drugs for Ultrasound imaging of blood flow and tissue perfusion
- Also known as: Definity®, Definity
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing